Last reviewed · How we verify
NCT04271800
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Phase 1, PHASE2 trial testing CD19 CAR-T cells in Leukemia in 40 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Chongqing Precision Biotech Co., Ltd |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 December 2019 |
| Primary completion | 31 December 2023 |
| Estimated completion | 1 July 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD19 CAR-T cells — full drug profile →
Conditions studied
- Leukemia — all drugs for Leukemia →
- Lymphoma — all drugs for Lymphoma →
- Leukemia, B-Cell — all drugs for Leukemia, B-Cell →
- Leukemia, Lymphocytic, Chronic, B-Cell — all drugs for Leukemia, Lymphocytic, Chronic, B-Cell →
Sponsor
Chongqing Precision Biotech Co., Ltd — full company profile →
Who can join
Adults 3 to 75, any sex, with Leukemia or Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Griggio V, Perutelli F, Salvetti C, Boccellato E, et al · · 2020 · cited 54× · PMID 33312177 · DOI 10.3389/fimmu.2020.594556
Verify or expand the search:
- PubMed search for NCT04271800
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CD19 CAR-T cells
Trials testing the same drug.
- NCT07252336 — A Multicenter Study of CAR-T Cells in Primary Ph+All · Phase 2 · recruiting
- NCT07161193 — Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases · Phase 1, PHASE2 · not yet recruiting
- NCT06710717 — Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE) · Phase 1 · recruiting
- NCT06585514 — Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus · Phase 1, PHASE2 · recruiting
- NCT04661020 — CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma · Phase 2 · recruiting
Other recruiting trials for Leukemia
Currently open trials in the same condition.
- NCT07405424 — Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia · NA · recruiting
- NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07148180 — A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: · Phase 1, PHASE2 · recruiting
Other Chongqing Precision Biotech Co., Ltd trials
Trials by the same sponsor.
- NCT07181720 — CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · Phase 1 · recruiting
- NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
- NCT07184450 — Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases · Phase 1 · recruiting
- NCT07239323 — In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies · Phase 1 · recruiting
- NCT06892145 — Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04271800 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chongqing Precision Biotech Co., Ltd
- Last refreshed: 18 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04271800.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing